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A high-resolution carboxypeptidase-Zn2+-citrate complex was studied by X-ray diﬀraction and enzyme kinetics for the ﬁrst time.
The citrate molecule acts as a competitive inhibitor of this benchmark zinc-dependent peptidase, chelating the catalytic zinc ion in
the active site of the enzyme and inducing a conformational change such that carboxypeptidase adopts the conformation expected
to occur by substrate binding. Citrate adopts an extended conformation with half of the molecule facing the zinc ion, while the
other half is docked in the S1  hydrophobic speciﬁcity pocket of the enzyme, in contrast with the binding mode expected for a
substrate like phenylalanine or a peptidomimetic inhibitor like benzylsuccinic acid. Combined structural and enzymatic analysis
describes the characteristics of the binding of this ligand that, acting against physiologically relevant zinc-dependent proteases,
may serve as a general model in the design of new drug-protecting molecules for the oral delivery of drugs of peptide origin.
1.Introduction
Carboxypeptidase A (CPA) is the canonical form of the M14
family of peptidases, an important group of physiologically
relevant enzymes [1]. M14 peptidases such as CPA and
CPB, synthesized in the pancreas and secreted into the
gastrointestinal tract, are the major zinc-dependent enzymes
responsible for the release of the C-terminal amino acid
residue from food protein [2]. Carboxypeptidase activity in
the gastrointestinal tract may be modulated by dietary zinc
[3, 4] or can be inhibited by some organic food components
[5–7]. Also, changes in the genomic expression levels may
control carboxypeptidase enzyme activity in digestion [8]. In
other compartments of the body, diﬀerent CPs participate
in tightly regulated processes such as, for instance, the
maturation of physiologically active peptide hormones.
Moreover, M14 peptidases are therapeutically interesting
molecules because of their involvement in acute pancreatitis
[9–11], cancer [12–14], diabetes [15, 16], ﬁbrinolysis [17],
and inﬂammation [18].
Carboxypeptidase A structure reveals that the catalytic
zinc ion is coordinated by three protein residues and by one
water molecule which is displaced upon substrate binding.
The substrate is held in the binding pocket through an
ion pair between its C-terminal carboxylate group and
the guanidinium side chain of Arg145 and two additional
hydrogen bonds with Asp144 and Tyr248. The enzyme-
substrate interaction is additionally stabilized by the overall
hydrophobic character of the binding pocket which reduces
competitive solvation by water molecules [19]. The CPA
catalytic mechanism has attracted much attention as a
model for zinc-dependent proteases and as such routinely
investigated [20–25]. In the two most widely accepted
mechanisticpathways,thezincionwouldplayafundamental
role either by activating the amide carbonyl of the substrate
or by creating a zinc-water nucleophile that directly attacks
the amide group [26]. Chelation of the zinc ion is an
important aspect in the development of chemotherapeutic
agents targeted to this class of enzymes [27, 28]a sw e l la s
in the development of new drug protective molecules for the2 Enzyme Research
administration of pharmacologically important peptide and
protein drugs [29, 30].
In the course of our investigations on M14 peptidases
and organic synthetic inhibitors [31], we obtained a high
resolutionCPA-Zn2+-citrateternarycomplexstructure.Such
an interaction can be understood from the metal-chelating
properties of the citrate anion as citrate, a major component
in snake venom, is believed to inactivate metal proteases in
the prey assisting in venom toxin movement [32]. Database
searches revealed only a few instances in which a biological
macromolecule-Zn2+-citrate system had been studied at
the structural level; surprisingly, none of these involve a
biologically active zinc-dependent peptidase. It is interesting
to note that in a recent investigation citrate inhibition of
carboxypeptidase enzymatic activity has been linked to drug
permeation-enhancing properties of the carrier molecule
[33]. Thus, the high-resolution structural determination of
the CPA-Zn2+-citrate ternary complex presented here along
with the kinetic evaluation of citrate inhibition of the CPA
catalytic mechanism is intended to gain further insights into
the interactions between this coligand of pharmaceutical use
and the model zinc-dependent intestinal protease.
2. Methods
2.1. Protein Crystallization and Structure Solution. Lyophi-
lized bovine pancreas carboxypeptidase A (Sigma, St. Louis,
MO) was dissolved in buﬀer 0.02M Tris pH 7.5/1.2M LiCl
and then desalted and concentrated in Centricon centrifugal
ﬁlter devices (Millipore, Billerica, MA, USA) against 5mM
Tris, pH 7.5. During a screening to analyze the structures of
CPA-organic inhibitor complexes, CPA crystals were grown
from a 2μL:2μL mixture of enzyme solution (10mg/mL
in 0.02M Tris, pH 7.5) and precipitant (20% PEG 3, 350,
0.2M NH4Cl, 0.02M Tris, pH 7.0) by the vapour diﬀusion
method. Crystals suitable for X-ray diﬀraction analysis were
grownin thesitting drop setting in anincubatoratthesteady
temperature of 289K. The largest crystals were harvested
and transferred to a new 2μL drop containing the reservoir
solution plus a millimolar amount of inhibitor solution.
As crystal damage was evident, sequential soakings with
increasinginhibitorconcentrationswereperformed.Crystals
were harvested, brieﬂy bathed in cryoprotectant buﬀer (i.e.,
the reservoir solution with added 30% glycerol), ﬂash frozen
in the nitrogen stream, and diﬀracted. Structure determi-
nation was made with the molecular replacement method
using native CPA (PDB entry 2ctb) as the model. Extra
electron density accounting for three planar carboxylate
groups was clearly evident in the region near the catalytic
zinc ion. The shape of this density was easily interpreted
as a citrate molecule. Sodium citrate, a buﬀer used to
dissolve the inhibitor, would be the probable source of the
ligand seen in the electron density maps. No trace of other
inhibitor molecules is seen in the maps. The reﬁnement
progressed to convergence and reached a good agreement
between the model and the experimental data as shown
by the statistics listed in Table 1.P r o t e i nX - r a yd i ﬀraction
experiments were performed at the X11 and X13 beamlines
of the EMBL (European Molecular Biology Laboratory)-
Outstation at DESY (Deutsches Elektronen Synchrotron),
Hamburg, Germany. X-ray diﬀraction data was processed
withAutomar(MarresearchGmbH,Norderstedt,Germany).
The CCP4 suite [34] and programs PHASER [35]a n d
REFMAC [36] were used in diﬀerent stages of structure
solution and reﬁnement. MolProbity [37] and PROCHECK
[38] were employed to check the protein coordinates against
reference geometric values. Model building and map ﬁtting
were made with Coot [39]. Alltheﬁnalﬁgureswereprepared
with Pymol (http://www.pymol.org/).
2.2. Kinetic Analysis. Benzylsuccinic acid (BzlSA), sodium
citrate, and other reagents were from Sigma (St. Louis, MO).
AAFP substrate was from Bachem (Bubendorf, Switzerland).
The working solutions included various concentrations of
each compound and one AAFP substrate concentration,
usually at the Km v a l u e .T h eﬁ n a la s s a y e dc o n c e n t r a t i o n s
were stepwise varied between 1nM and 10mM (for BzlSA)
and between 10μM and 100mM (for citrate). One blank
well was used as the control without inhibitor, and the
experiments were performed at least by duplicate. The
enzyme concentration was adjusted for the kinetic mea-
surements to take place within the initial velocity regime.
Changes in absorbance due to proteolytic activity were
followed continuously in a multimode plate reader Wallac
1420 Victor3 system (PerkinElmer Life Sciences, Waltham,
MA, USA). The kinetic measurements were carried out at
roomtemperatureusing96-wellmicrotiterplates(IwakiCo.,
Japan).KineticactivitydatawasthentreatedwiththeGraph-
P a dV e r s i o n5 . 0p a c k a g e( G r a p h P a dS o f t w a r e ,S a nD i e g o ,
CA, USA). After ensuring a good agreement between the
experimental observations and the inhibition model, the Ki
value was calculated from the IC50 following the procedure
of Cheng and Prussoﬀ [40]. The goodness of ﬁt between
theinhibitionmodelusedandtheexperimentalobservations
was excellent as indicated by the R2 parameters, 0.9971 and
0.9822 for BzlSA and citrate, respectively, and by the span
of the 95% conﬁdence interval, in which the Ki values lie
between0.39–0.67μMand3.5–7.0mMforBzlSAandcitrate,
respectively.
3. Results and Discussion
3.1. Analysis of Structural Data. Although citrate anion is
widely used as a buﬀer in crystal structure determinations,
out of the few examples of zinc-dependent proteases bound
to this ligand that can be found in the RCSB PDB database,
only two hits, namely, human procarboxypeptidase B (entry
1kwm) and porcine procarboxypeptidase A (1pca), were
retrieved when searching for carboxypeptidases. Neither
of these structures shows citrate in coordination with the
catalytic zinc ion, presumably because the presence of the
prodomain in both zymogen structures hinders the access to
the active site of the enzyme, but the citrate anion resides
on the protein’s surface exposed to external solvent water
molecules. This observation suggests that citrate does bind
to exosites in digestive immature proteases, but no structural
evidence on its ability to bind to the catalytic machinery
of a mature enzyme is available yet. A further query toEnzyme Research 3
Table 1: Statistics of data collection and reﬁnement for citrate-bound CPA.
Parameters Value
Wavelength used during data collection 0.8123 ˚ A
Unit cell constants
a = 40.61 ˚ A, b = 57.01 ˚ A,
c = 60.61 ˚ A
α = 90.0◦, β = 102.4◦, γ = 90.0◦
Resolution range 20.24–1.70 ˚ A
Space group P21 (1mol/asymmetric unit)
Number of measured reﬂections 185,198
Number of unique reﬂections 29,594
Rmerge
a (overall/outermost shell) 7.8/27.9%
Completeness & multiplicity (overall/outermost shell) 99.6/99.8%
2.9/3.1
I/σI (overall/outermost shell) 18.1/3.5
Reﬂections used for reﬁnement (total/test set) 26,403/893
Crystallographic Rfactor
b/Rfree
c 17.8/20.5%
Deviation from ideality
r.m.s.d. bond lengths 0.009 ˚ A
r.m.s.d. bond angles 1.18◦
Number of protein atoms/total atoms 2,415/2,691
B-factor statistics (˚ A2)
Overall B-factor/Wilson plot B-factor 17.6/25.4
Catalytic domain, main/side chain 16.2/17.0
Zn2+ (1 in total/1mol per monomer) 13.6
Citrate atoms (13 in total/1mol per monomer) 20.6
Glycerol atoms (36 in total/6mols per monomer) 35.4
Solvent atoms (214 in total) 26.3
Protein geometryd
Ramachandran favored 96.7% (294 of 304 residues)
Ramachandran allowed 99.7% (303 of 304 residues)
Ramachandran outliers 0.3% (1 of 304 residues, Ser-199)
Residues with bad bonds/angles 0.00/0.00%
Rotamer outliers 0.33%
Notes: aRmerge = ΣhklΣj=1 to N |Ihkl −Ihkl,( j)|/ΣhklΣj=1 to NIhkl(j), where N is the redundancy of the data. The outermost shell is 1.75–1.70 ˚ A.
bRfactor = Σhkl||Fobs|−|Fcalc||/Σhkl|Fobs|, where the Fobs and Fcalc are the observed and calculated structure factor amplitudes of reﬂection hkl.
cRfree = is equal to Rfactor for a randomly selected 3.3% subset of reﬂections that were not used in reﬁnement.
dAccording to Molprobity [37].
the RSCB PDB revealed a total of 13 macromolecule-zinc-
citrate structures, none of which involve digestive enzymes.
Therefore, the present crystal structure determination rep-
resents the ﬁrst example of a metal-dependent, fully active,
physiologically relevant protease in a ternary complex with
citrate. A crystal belonging to the monoclinic space group
P21 that diﬀracted beyond 1.70 ˚ A was characterized in this
study; crystallographic and reﬁnement statistics details are
presented in Table 1. The atomic coordinates and structure
factors have been validated and deposited with the RCSB
PDB with accession code 3kgq.
3.2. The Binding of Citrate to the Catalytic Centre in the
CPA Active Site. One citrate anion per carboxypeptidase-
Zn2+ cation was identiﬁed from the electron density maps
(Figure 1). Citrate binds in an extended conformation to
the catalytic centre of the enzyme’s active site, where the
amide bond is be hydrolyzed, across subsites S1 (deﬁned
by residues Arg127 and Glu270, which are involved in the
nucleophilic attack of the scissile amide carbon) and S1 
(Asn144, Arg145, and Tyr248, which anchor and stabilize the
peptide substrate). All but one of the four functional groups
from citrate make important interactions with the metal and
several ligands from the protein (Table 2 and Figure 2).
The zinc ion is bidentately chelated by citrate oxygen
atoms O1 and O2, both atoms lying in the proximity
of two zinc ligands from the protein (His69 and Glu72).
Oxygen atoms from two diﬀerent carboxylate groups are
hydrogen bonded to Arg127. The nucleophile Glu270 forms
a strong hydrogen bond to one carboxylate and the hydroxyl
group. An ion pair is formed between oxygen atoms O5
and O6 from citrate and the guanidinium side chain of4 Enzyme Research
E270 Y248
R145 H196
H69
E72
Figure 1: Partial view of the carboxypeptidase-Zn2+-citrate com-
plex structure localized around the citrate ligand. The ligand is
coloured green while protein atoms are in grey. Oxygen and
nitrogen atoms are red and blue, respectively. The Zn2+ ion is
depicted as a sphere in yellow. Relevant residues for binding are
shown as sticks and labelled. Polar interactions are shown as solid
lines in black. The 2Fo-Fc map, calculated by deleting citrate and
Zn2+ coordinates, is contoured at 1.0 sigma (gold mesh).
Table 2: Geometric details of the interaction between protein
residues and the citrate ligand.
Protein residue ID Ligand atoms Distance (˚ A)
Protein Citrate
Zn Zn2+ O2 2.1
O1 2.7
His69 Nδ1O 2 3 . 0
Glu72 Oε2O 2 3 . 2
Oε2O 1 3 . 3
Arg127 Nη1O 2 3 . 2
Nη2O 5 3 . 0
Asn144 Nδ2O 6 2 . 9
Arg145
Nη1O 5 3 . 2
Nη1O 6 2 . 8
Nη2O 5 2 . 7
Ser197 O O1 3.1
Tyr248 Oη O5 2.6
Glu270
Oε1O 1 2 . 4
Oε2O 1 3 . 0
Oε2O 7 2 . 8
HOH213 OO 4 2 . 6
OO 3 3 . 3
HOH109 O O3 2.6
HOH191 O O1 2.9
Arg145. These atoms make additional interactions with the
other S1  residues, Asn144 and Tyr248. The latter residue
has been identiﬁed as a key player in the CPA catalyzed
mechanism by site-speciﬁc mutagenesis studies [24]. The
conformational change suﬀered by Tyr248 upon ligand
binding is well documented: the aromatic ring switches by
120◦ its location between the solvent exposed “open” to the
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Figure 2: The structures of CPA bound to the peptidomimetic
BzlSA (a) and citrate (b) are schematically shown. Important
residues for binding the zinc ion (sphere) are included. Water
molecules shielding citrate are shown as wavy lines.
“closed” conformation with the phenolic hydroxyl pointing
to the catalytic zinc [41, 42]. In this paper, Tyr248 is in the
closed conformation expected to occur when the active site
of the enzyme is occupied. As seen in other CPA-bound
structures, the water molecule is displaced from the zinc
coordination sphere by a carboxylate from the ligand and
the citrate molecule binds to CPA in a manner reminiscent
of the succinate-based ligands such as the benchmark
inhibitor benzylsuccinic acid (BzlSA). As will be commented
next, while the aromatic ring of BzlSA is buried in the
hydrophobic pocket of CPA, the carboxylate group of citrate
that occupies the corresponding edge of the molecule adapts
its conformation to this speciﬁc enzyme’s environment.
3.3. Citrate Burial in the Hydrophobic Pocket of CPA. Like
citrate, BzlSA chelates zinc and forms an ion pair with
Arg145 and hydrogen bonds to catalytically key residues
like Tyr248, but the two molecules also display considerable
diﬀerences in binding to the enzyme (Figure 3). FromEnzyme Research 5
(a)
(b)
Figure 3: Comparison of carboxypeptidase-bound structures. (a)
CPA in complex with BzlSA (PDB entry 1cbx). (b) CPA with bound
citrate (this work). BzlSA and citrate are shown magenta and green,
respectively. Ala250 and Ile255, enclosing the ligand, are in orange.
Note the location of two water molecules (spheres in red) at (b),
masking hydrophobic residues at the bottom of the active site.
Hydrogen bond interactions are as dashed lines in black. Both
structures are shown in similar orientation.
inspection of the crystal structure in complex to CPA (PDB
entry 1cbx), BzlSA extends towards the bottom of the active
site cleft with an aromatic ring that mimics a phenylalanine
residue. Side chains Leu203, Ile243, Ala250, Gly253, Ile255,
and Thr268 deﬁne the hydrophobic pocket that harbours the
speciﬁcity-determinant residue in the M14 peptidase family,
which for CPA is Ile255. This hydrophobic pocket is best
suited to accommodate an aromatic ring, and Ile255 makes
hydrophobic interactions with this part of the inhibitor
(Figure 3(a)).
The third carboxylate group from citrate is the only one
shielded from contact to CPA. Each one of the oxygen atoms
of the carboxylate group, O3 and O4, makes strong hydrogen
bonds to water molecules, which in turn are hydrogen
bonded to otherwatermolecules and amino acidside chains.
Thus, this ionisable group lies at least about 3.5 ˚ Aa p a r tf r o m
the wall of the hydrophobic pocket (the closest residue is
Ala250) and at more than 7 ˚ A from Ile255. Compared to
the BzlSA bound structure, the conformation of the latter
residue is substantially shiftedas measured by the Cα-Cβ-
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Figure 4: Fit of a competitive inhibition model (continuous line-
squares, BzlSA; dashed line-triangles, citrate) to the experimental
observations.
Table 3: Kinetic parameters of BzlSA and citrate inhibition.
Compound Type of
inhibition
Substrate Ki (μM) Reference
BzlSA
competitive Hipp-Phea 1.1 [43]
competitive O-Cl-Pheb 0.2 [44]
competitive N-Ac-PSPc 0.51–0.61 [49]
competitive AAFPd 0.52 This work
citrate competitive AAFPd 5,000 This work
Notes: aHippuryl-L-phenylalanine.
bO-(trans-p-chlorocinnamoyl)-L-β-phenylacetate.
cN-acetyl-phenylalanyl-3-thiaphenylalanine.
dN-(4-methoxyphenylazoformyl)-L-phenylalanine.
Cγ1-Cδ1 torsion angle: 160.3◦ and −37.7◦ for the BzlSA and
citrate CPA-bound forms, respectively. This rearrangement
oftheIle255sidechainwouldreﬂecttheabilityoftheenzyme
to adapt the hydrophobic pocket to the features of the ligand
molecule.
3.4. Kinetic Assays of CPA Ligands. Kinetic activity measure-
ments were carried out to determine the ability of citrate to
inhibit the CPA catalyzed reaction. The measurements were
made in parallel with BzlSA to provide a direct comparison
with this standard inhibitor. The nonlinear global ﬁtting
of the experimental data to a competitive inhibition model
was excellent (Figure 4). Besides, the shape of the citrate
inhibition curve resembles that of BzlSA whose Ki is in
excellent agreement with values obtained in previous works
(Table 3).
From Table 3, it is evident that citrate performs as
a very weak CPA inhibition compared to BzlSA, a likely
consequence of the presence of the aromatic moiety in the
latter. BzlSA was designed as a by-product analogue, that
is, it retains features of the cleaved products of the CPA
catalytic reaction [43] in such as way that the aromatic6 Enzyme Research
moiety docks into the hydrophobic pocket of the enzyme,
displacing water molecules at the bottom of the active
site cleft. This displacement, together with the movement
of Tyr248, substantially facilitate the enzymatic activity by
creating an overall hydrophobic environment. It is well
documented that amino acid substrates and products are
very weak CPA inhibitors. For example, L-Phe is, like it has
been calculated here for citrate, a 5mM CPA inhibitor [43].
Although citrate would be easily displaced by the substrate
AAFP when competing for binding to CPA in the in vitro
experimental assays, a completely diﬀerent scenario may be
possible in vivo such that citrate could be equally well suited
asthenaturalsubstratesaretobindtotheactivesiteofmetal-
dependent proteases.
4. Conclusion
Citric acid has intestinal absorption enhancing eﬀects and is
widely used in drug formulations. Recent evidence demon-
strated that the citrate salt of chitosan has a drug penetration
enhancement and that this eﬀect is linked to the inhibition
of metal-dependent enzymes like leucine aminopeptidase
(a membrane protease) and the luminal protease CPA [44,
45]. In line with these observations, we report further
structural and kinetic evidence of the interaction between
CPA and citrate, in which the organic anion chelates the zinc
cation at the active site of the enzyme. The citrate mode
of binding resembles that of the peptidomimetic substrate
analogue benzylsuccinic acid, which also coincides with
citrate in being a competitive CPA inhibitor. The Ki value
for citrate is much weaker than that of benzylsuccinic acid
but comparatively similar to that of simple amino acids,
suggesting that citrate would compete for the in vivo binding
of zinc at the active site of intestinal enzymes.
There is a wide range of digestive protease inhibitors
with potential as peptide drug-protecting agents that, like
commonly used excipients, may be associated with some
drawbacks as elevated costs or risk of toxic side eﬀects
[46, 47]. Eﬀorts to combine a protease inhibitor and a drug
permeation enhancer in one single molecule to increase
the stability and absorption of peptide or protein drugs
are an increasingly investigated matter [48]. As recently
reported [33], citrate, a commonly used excipient, may be
an example of such type of molecules. The analysis of the
newly determined carboxypeptidase-Zn2+-citrate complex
structure might help in the structure-guided design of newer
drug protecting compounds targeted to metal-dependent
proteases.
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